Literature DB >> 1317668

Large cell carcinoma of the lung with neuroendocrine differentiation. A comparison with large cell "undifferentiated" pulmonary tumors.

M R Wick1, L C Berg, M I Hertz.   

Abstract

Twelve large cell carcinomas of the lung showing evidence of neuroendocrine differentiation (LCCND) were compared with 15 other large cell pulmonary tumors that lacked such features (NELCUC). All lesions were composed of partially necrotic, nested, or sheet-like arrays of mitotically active, nucleolated large cells that were at least twice the size of those seen in small cell carcinomas. Examples of LCCND were defined by immunoreactivity for neuron-specific enolase, Leu-7, synaptophysin, and chromogranin-A, and by their content of neurosecretory granules on electron microscopy. NELCUCs were devoid of these immunohistologic and ultrastructural features. There were six women and six men with LCCND, who ranged in age from 38 to 82 years. Of nine individuals in this group with Stage T1NOMO or T2NOMO disease at diagnosis, five (55%) died of their neoplasms within 3 years of diagnosis; three more (33%) have recurrent or persistent tumors and are likely to die as a result. On the other hand, 47% of patients with NELCUC of similar stages are free of disease after a similar follow-up period. LCCND is a distinctive clinicopathologic disease and should not be classified with unspecified large cell anaplastic carcinomas of the lung. Its behavior is potentially aggressive and may justify consideration of a specialized treatment protocol. Because electron microscopic evaluation of immunohistologic features must be done to recognize LCCND, it is probably underdiagnosed.

Entities:  

Mesh:

Year:  1992        PMID: 1317668     DOI: 10.1093/ajcp/97.6.796

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Authors:  Jarushka Naidoo; Maria L Santos-Zabala; Tunc Iyriboz; Kaitlin M Woo; Camelia S Sima; John J Fiore; Mark G Kris; Gregory J Riely; Piro Lito; Afsheen Iqbal; Stephen Veach; Stephanie Smith-Marrone; Inderpal S Sarkaria; Lee M Krug; Charles M Rudin; William D Travis; Natasha Rekhtman; Maria C Pietanza
Journal:  Clin Lung Cancer       Date:  2016-01-21       Impact factor: 4.785

2.  Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update.

Authors:  Dongfeng Tan; Dani S Zander
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

3.  Multicystic metastatic carcinoid to brain: case report.

Authors:  K A Greene; J A Anson; J A Martinez; R F Spetzler; P C Johnson
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

4.  Characteristics of two cell lines derived from a histologically undifferentiated bronchial carcinoma expressing neuroendocrine markers.

Authors:  S Wright-Perkins; M R Daniel; C Walker
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-07       Impact factor: 2.416

5.  Clinical features of bronchogenic large cell carcinoma confirmed by surgical resection.

Authors:  Moo Suk Park; Dong Hwan Shin; Kyung Young Chung; Jae Hee Cheong; Jae Ho Chung; Do Hoon Kim; Se Kyu Kim; Joon Chang; Joo Hang Kim; Sung Kyu Kim; Young Sam Kim
Journal:  Korean J Intern Med       Date:  2003-12       Impact factor: 2.884

6.  Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review.

Authors:  Hong Tang; Hongyan Wang; Shaoyan Xi; Chunyu He; Yuxi Chang; Qiming Wang; Yufeng Wu
Journal:  Onco Targets Ther       Date:  2018-05-07       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.